Equities research analysts expect Allakos Inc (NASDAQ:ALLK) to announce ($0.24) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Allakos’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.26). The company is expected to announce its next quarterly earnings results on Wednesday, December 5th.
According to Zacks, analysts expect that Allakos will report full year earnings of ($1.07) per share for the current fiscal year, with EPS estimates ranging from ($1.20) to ($0.93). For the next financial year, analysts expect that the company will post earnings of ($1.21) per share, with EPS estimates ranging from ($1.50) to ($0.92). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Allakos.
Allakos (NASDAQ:ALLK) last posted its quarterly earnings results on Wednesday, August 29th. The company reported ($4.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($3.90).
A number of research firms have issued reports on ALLK. Jefferies Financial Group began coverage on shares of Allakos in a research report on Monday, August 13th. They set a “buy” rating and a $53.00 price target for the company. William Blair began coverage on shares of Allakos in a research report on Monday, August 13th. They set an “outperform” rating for the company. Goldman Sachs Group began coverage on shares of Allakos in a research report on Monday, August 13th. They set a “neutral” rating and a $31.00 price target for the company. Finally, Zacks Investment Research raised shares of Allakos from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Monday.
ALLK opened at $40.10 on Monday. Allakos has a 12-month low of $26.00 and a 12-month high of $49.10.
In other Allakos news, Director Daniel Janney purchased 250,000 shares of Allakos stock in a transaction on Monday, July 23rd. The stock was bought at an average cost of $18.00 per share, with a total value of $4,500,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Venture Fund (Ohi Rivervest II bought 111,111 shares of the business’s stock in a transaction dated Monday, July 23rd. The shares were purchased at an average cost of $18.00 per share, with a total value of $1,999,998.00. The disclosure for this purchase can be found here.
Allakos Company Profile
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Featured Story: Return on Investment (ROI)
Get a free copy of the Zacks research report on Allakos (ALLK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.